HCA Healthcare, Inc.
NYSE:HCA · New York Stock Exchange
-$12.05 today
Vol 2.63M · Avg 1.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-112.6%
avg -112.1%
ROIC
18.5%
avg 16.0%
ROA
11.2%
avg 9.2%
Analysis
ROIC is currently the strongest return metric at 18.5% versus its period average of 16.0%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Samuel N. Hazen | Chief Executive Officer & Director | $7.53M | — | 66 | $86,165.00 | 0.04% |
Jon Mack Foster | Executive Vice President & Chief Operating Officer | $3.76M | — | 64 | $28,950.00 | 0.01% |
Michael A. Marks | Chief Financial Officer & Executive Vice President | $3.49M | — | 56 | $46,576.00 | 0.02% |
Michael R. McAlevey | Executive Vice President and Chief Legal & Administrative Officer | $3.17M | — | 62 | $12,576.00 | <0.01% |
Michael S. Cuffe | Executive Vice President & Chief Clinical Officer | $3.16M | — | 60 | $12,576.00 | <0.01% |
Thomas F. Frist Jr. | Founder & Chairman Emeritus | $17,973.00 | — | 87 | $15,858.00 | <0.01% |
Wendy Warren | Senior Vice President and Chief Ethics & Compliance Officer | — | — | — | — | — |
Christopher F. Wyatt | Senior Vice President, Principal Accounting Officer & Controller | — | — | 48 | $44,379.00 | 0.02% |
Frank George Morgan | Vice President of Investor Relations | — | — | — | $10,121.87 | <0.01% |
Chad J. Wasserman | Senior Vice President & Chief Information Officer | — | — | — | $1,576.31 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$32.73M
Net Sentiment
$32.73M
Net selling
Most Active
HAZEN SAMUEL N
7 transactions
1–10 of 14
Analysis
Insiders reported 0 buys worth $0.00 and 14 sells worth $32.73M over the last 12 months. That adds up to net selling of $32.73M. HAZEN SAMUEL N was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +12.7% | +16.4% (15yr)3 analysts |
| Revenue | N/A | N/A | +6.3% | +6.2% (15yr)6 analysts |
| Net Income | N/A | N/A | +9.9% | +11.7% (15yr)6 analysts |
| EBIT | N/A | N/A | +7.4% | +6.9% (15yr)6 analysts |
Analysis
Recent growth has been strongest in EPS at +12.7% over three years. Forward estimates point to EPS at +16.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Pfizer Inc.
NYSE:PFE
$143.91B
CVS Health Corporation
NYSE:CVS
$125.53B
Stryker Corporation
NYSE:SYK
$119.17B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$114.84B
Bristol-Myers Squibb Company
NYSE:BMY
$110.06B
GSK plc
NYSE:GSK
$101.88B
Sanofi
NASDAQ:SNY
$101.47B
Medtronic plc
NYSE:MDT
$101.45B
McKesson Corporation
NYSE:MCK
$87.79B
Tenet Healthcare Corporation
NYSE:THC
$14.90B
Who manages HCA?
HCA Healthcare, Inc. (HCA) lists 10 active executives. The top listed executive is Wendy Warren, Senior Vice President and Chief Ethics & Compliance Officer.
Are HCA insiders buying or selling?
Recent insider activity shows net selling of $42.20M.
Explore More
Continue the stock analysis
Jump to another research area for this company.